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Abstract
The immunological roles of B-cells are being revealed as increasingly complex by functions that are largely beyond
their commitment to differentiate into plasma cells and produce antibodies, the key molecular protagonists of
innate immunity, and also by their compartmentalisation, a more recently acknowledged property of this immune
cell category. For decades, B-cells have been recognised by their expression of an immunoglobulin that serves the
function of an antigen receptor, which mediates intracellular signalling assisted by companion molecules. As such,
B-cells were considered simple in their functioning compared to the other major type of immune cell, the
T-lymphocytes, which comprise conventional T-lymphocyte subsets with seminal roles in homeostasis and
pathology, and non-conventional T-lymphocyte subsets for which increasing knowledge is accumulating. Since the
discovery that the B-cell family included two distinct categories — the non-conventional, or extrafollicular, B1 cells,
that have mainly been characterised in the mouse; and the conventional, or lymph node type, B2 cells — plus the
detailed description of the main B-cell regulator, FcγRIIb, and the function of CD40+ antigen presenting cells as
committed/memory B-cells, progress in B-cell physiology has been slower than in other areas of immunology.
Cellular and molecular tools have enabled the revival of innate immunity by allowing almost all aspects of cellular
immunology to be re-visited. As such, B-cells were found to express “Pathogen Recognition Receptors” such as
TLRs, and use them in concert with B-cell signalling during innate and adaptive immunity. An era of B-cell
phenotypic and functional analysis thus began that encompassed the study of B-cell microanatomy principally in
the lymph nodes, spleen and mucosae. The novel discovery of the differential localisation of B-cells with distinct
phenotypes and functions revealed the compartmentalisation of B-cells. This review thus aims to describe novel
findings regarding the B-cell compartments found in the mouse as a model organism, and in human physiology
and pathology. It must be emphasised that some differences are noticeable between the mouse and human
systems, thus increasing the complexity of B-cell compartmentalisation. Special attention will be given to the
(lymph node and spleen) marginal zones, which represent major crossroads for B-cell types and functions and a
challenge for understanding better the role of B-cell specificities in innate and adaptive immunology.
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Review and conclusion
Introduction
A key property of B-cells is that these unique cells of the
adaptive immunity branch are the only cells capable of
editing epitope-specific tools, i.e., antibodies (Abs), by ra-
pidly superimposing genetic events that end with som-
atic mutations and class switching to ensure extremely
efficient immune responses to a panoply of pathogens,
particularly T-dependent (TD) antigens (Ags). Although
progress is still being made in understanding the intricate
mechanisms of this extremely complex genetic event, this
function of B-cells is considered their classical property.
Evidence is growing that innate immunity is regaining the
importance it probably lost when the much-sought-after
function of adaptive immunity and the highly sophisti-
cated role of conventional lymphocytes were finally under-
stood. Intriguingly, while many cell subsets are specific to
each branch of immunity, it is now apparent that B-cells
have almost equivalent roles in either branch, and their
importance as innate immune cells has now been recog-
nised with the discovery of functional and tissue-specific
subsets in bone marrow (BM), secondary lymphoid organs
and mucosae. B-cells may behave as one-man-bands,
using the most appropriate instrument (B-cell receptor,
Toll-like receptors, cytokine/chemokine-receptors, etc.)
for each situation, but they are also highly plastic in their
capacity to produce cytokines. This property was only re-
cently appropriately acknowledged, in comparison to the
champion cells for polarising immune responses such as
T-cells, dendritic cells (DCs) or macrophages (and now
platelets). In hindsight, however, this property could have
been deduced from one of the first descriptions of how a
lymphocyte was reprogrammed, i.e., after infection with
Epstein-Barr virus (EBV) through its unique receptor,
CR2/CD21 [1]. Paradoxically, the rediscovery of the roles
and functions of B-cell subsets in innate immunity pro-
vides the “non-classical” (new) part of the story, which it-
self is far from being complete, since many discrepancies
between mouse and human systems plead for novel exten-
sive research efforts to fill in the gaps.
Arising questions on B-lymphocytes
Decades ago, lymphocytes were discovered as the major
tools of specific immunity, now defined as adaptive im-
munity, which has unique characteristics based on clonal
differentiation and a repertoire of Ag recognition. A
long-term paradigm then arose, which postulated that B-
cells underwent terminal differentiation into plasma cells
and that the majority were then confined to antibody
(Ab) production, while some differentiated B-cells were
spared from this terminal pathway to constitute a pool
of memory B-cells. Memory as well as activated B-cells
were then shown to efficiently present Ags to T-cells
and undergo mutual activation/differentiation processes
that involve cytokines and several pairs of co-stimulatory
molecules, including the well-known CD40/CD40L pair
[2]. The constitutive expression of CD40 was ascri-
bed first to B-cells, and then extended to most Ag
presenting cells (DC and macrophages); this property
helped to decipher the Ag presenting cell (APC) func-
tion of activated/memory B-cells and their use along-
side Major Histocompatibility or MHC molecules [3].
The co-expression of MHC and of CD40 does not,
however, licence immune cells as APCs (e.g. platelets
possess such characteristics) [4].
B-cells were essentially described for their indispens-
able role in the so-called humoral (Ab-based) immunity,
and the machinery supporting their central functions
was thought to be essentially located in the germinal
centres (GCs) of lymph nodes and the spleen. Years
later, it was acknowledged that this functional microa-
natomy also concerned the mucosal equivalents of
lymph nodes, thus supporting mucosal immunity. With
further investigation, however, it became evident that B-
cells can exert a number of Ab-independent functions,
including capturing and concentrating Ags for presenta-
tion, producing cytokines, influencing T-cell and DC
responses, contributing towards distinct functions dur-
ing the immune response in vivo, affecting lymphoid tis-
sue structures, and even participating in tissue repair [5].
Around fifteen years ago, the conceptual barrier be-
tween specific and non-specific immunity was breached
and novel functions were ascribed to innate immunity. As
such, the role of almost every immune cell type was revis-
ited. There were few changes to some areas, e.g., conven-
tional T-cells, but novel and important functions have
been ascribed to non-conventional T-cells, NK-cells and
NKT-cells. The issue of B-cells was much more intriguing
for two main reasons: 1) the discovery/identification of
non-conventional B-cells; and 2) the identification of non-
self infectious danger sensors or receptors (Rcs), which
are thought to characterize innate immunity and are
abundantly-expressed on B-cells. Indeed, the concept of
non-self-infectious danger was subsequently addressed
[6], Pathogen Associated Molecular Patterns (PAMPs)
were described on pathogens, and PAMP-counter ligands,
namely Pathogen Recognition Receptors (PRRs), were iden-
tified on the sensing and sentinel cells of innate immunity.
PRRs have remained extremely conserved throughout the
evolution of living organisms, with a key family being the
Toll-like Rcs or TLRs. We, and others, have further
described that a specific pattern of TLRs characterizes
every B-cell subset [7-10]. B-cells express Rcs for immu-
noglobulins (Ig) such as FcγRIIb/CD32 or FcεRII (CD23).
CD32 mediates inhibitory signals to BcR-activated B-cells,
but also authorizes the internalisation of immune com-
plexes. CD23 is essential for B-cell responses and distin-
guishes various immature and mature B-cell subsets.
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Complement Receptor 2 (CR2/CD21) is also found on
B-cells, where it amplifies BcR signalling through its asso-
ciation with CD19 and its downstream PI3K-dependent
signalling pathway [11]. CD21 also constitutes the unique
receptor for EBV, a herpes virus responsible for infectious
mononucleosis that is present in more than 85% of
healthy individuals in its latent form. Reactivation of EBV
is frequently observed in chronically HIV-infected patients
where it correlates with a higher frequency of circulating
transitional-like B-cells [12]. In addition, EBV+ B-cell
lymphomas are more frequent in HIV-infected patients
than in the general population [13].
The capacity of specific B-cell subsets to traffic
throughout the body is essential for sampling pathogens,
but also for their APC functions [14]. Accordingly, dis-
tinct programs of chemokine receptor expression were
also ascribed to the various B-cell subsets [15]. Whereas
most B-cells express CXCR4 and CXCR5 throughout the
course of B-cell differentiation, their balanced expression
is decisive for the emigration of immature B-cells from
BM into the spleen where CXCL12, the ligand of
CXCR4, is highly expressed in the red pulp [16]. In
steady-state conditions, the homing of mature naïve B-
cells into follicle anlagen is driven by strong expression
of CXCL13, the ligand of CXCR5, within the white pulp
[17], whereas the trafficking of memory B-cells beneath
CCL20-expressing epithelia is orchestrated by CCR6
[18]. Other chemokine receptors, in association with the
highly tissue-specific expression of their ligands, orches-
trate B-cell homing into intestinal mucosa (CCR9,
CCR10) or the skin (CCR4) in combination with integ-
rins and other adhesion molecules [16,19,20]. BcR or
CD40 signals and TLR agonists can tune the expression
of chemokine receptors [18,21-23] and therefore impair
their trafficking. As such, B-cells that were thought to be
almost “rude” cells according to the classical T-cell/B-
cell paradigm, are actually split into numerous subpopu-
lations that are functionally and spatially distinct.
Even more recent observations indicate that marginal
zone (MZ) and B1-like B-cells are engaged in the innate
arm of immune defence [24,25], and that immunoglobu-
lins (Igs) are comprised of two distinct molecular tools:
1) B-cell receptor/”specific” Abs; and 2) instruments of
the innate immunity branch, the so-called “polyreactive
Igs” that are largely associated with extrafollicular B1-
cells [26]. Besides MZ B-cells, recently defined B-cell
subsets have also captured the attention, including regu-
latory B-cells and CD21lo B-cells. Although B-cell phe-
notype characteristics and physiological functions need
to be better defined, recent studies in mice (and also in
humans) have clearly revealed their distinguished roles
in chronic infection, autoimmune disease and aging.
This confirms that B-cells are not only actors but also
key regulators in the immune response. This essay thus
aims to revisit B-cell immune physiology and reconsider
B-cells alongside more recent discoveries.
Marginal zone B-cells perform a key role in
microbial infection
The marginal zone: from structure to function
Besides its crucial role in filtering the blood and recyc-
ling red blood cell components and iron, the spleen is
also the largest secondary lymphoid organ of the body
after the discontinuous gut-associated lymphoid tissue
(GALT). Whereas the erythrocyte-rich “red pulp” leads
to a functionally slow bloodstream that favours blood fil-
tration, the organisation and functions of the lymphocyte-
rich “white pulp” closely resemble those found in lymph
nodes, with B-cell follicles and T-cell zones [27]. A highly
specialised micro-anatomical site surrounding the white
pulp, referred to as the MZ, constitutes a unique structure
that allows interactions between the key effectors of innate
and adaptive immunity.
The MZ is recognised as an anatomical site that
enables the cells leaving the bloodstream to transit from
the red to the white pulp. The MZ shows prominent
structural variation in different animal species: it is well
developed in rodents, intermediately developed in pri-
mates (human and non-human), and poorly developed
in the dog and cat [28]. Whereas the white pulp is spe-
cialised for adaptive responses (including Ab-based
responses to TD Ags), the MZ is more specialised for
the response to blood-borne pathogens (bacteria and
viruses), and in particular to T-independent (TI) Ags.
This functional distinction between TD and TI respon-
ses correlates with the presence of two distinct B-cell
populations: follicular and MZ B-cells, respectively. To
be fully efficient in inducing an Ab response, the lat-
ter B-cells must establish interactions with particular
subsets of macrophages, DCs and fibroblast-like cells,
and must respond to environmental cytokines in a well-
controlled spatiotemporal manner. Mouse macrophages
and MZ B-cells, firmly attached to sinus lining cells
and reticular fibroblasts bordering the MZ, are kept in
close proximity to each other and are locally expo-
sed to blood-borne pathogens. Two discrete subsets of
macrophages, the Marginal Metallophilic Macrophages
(MMM) and the Marginal Zone Macrophages (MZM),
populate the mouse MZ where they perform specialised
functions. Both MZM and a subset of MMM express
the type I scavenger receptor, MARCO (macrophage re-
ceptor with collagenous structure) [29]; however, MMM
characteristically express sialic acid-binding Ig-like
lectin-1 (Siglec-1, Sialoadhesin, CD169) and MZM char-
acteristically express the C-type lectin, SIGN-R1 (specific
intracellular adhesion molecule-3 grabbing non-integrin
homolog-related 1, the murine homolog of human DC-
SIGN — Dendritic cell-specific ICAM grabbing non
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integrin/CD209). MMM are essential for cross-presen-
tation of blood-borne antigens by splenic CD8+ DC
and initiation of the cytotoxic T-cell response [30], while
MZM preferentially act as phagocytic cells responsible
for clearing blood-borne pathogens harbouring TI Ags
and apoptotic material entering the spleen [31,32]. Once
MZM bind pathogens, they establish the direct cell–cell
interactions with MZ B-cells required for an efficient Ab
response [33,34]. As shown in various models of defi-
cient mice, B-cells are reciprocally required for normal
MZ development and maintenance as well as for the
presence and functions of MZM [29]. Even in the transi-
ent absence of MZ B-cells following administration of
LPS or FTY720 (a drug that blocks emigration from
lymphoid organs into blood and lymph), MZM quickly
lose SIGN-R1 expression and phagocytic activity [35].
In turn, the binding of pathogens to MZ B-cells and
the IgM response to polysaccharides only occur when
SIGN-R1-expressing MZM are present to first capture
pathogens [36]. Moreover, loss of MZM and MMM (by
treatment with clodronate-containing liposomes) leads
to MZ B-cell loss and impaired trapping of particulate
Ag. After treatment, the recovery of MZ B-cells is
delayed until MZM and MMM fully repopulate the MZ
[35]. In the absence of MZ B-cells, CD11c+ dendritic
cells normally concentrate in the MZ bridging channels
and are redistributed around the MZ, which likely
impairs the adaptive immune response as a consequence
[37]. Thus, a constant dialogue between MZ B-cells and
MZM, and likely with MMM, is mandatory for protect-
ing intact MZ architecture, as well as for efficient clear-
ance of pathogens and immune responses. MZM and
MMM also constitute important sources of type I inter-
feron (IFN) during murine infection by HSV (Herpes
Simplex Virus) and LCMV (Lymphocytic Choriomeningi-
tis Virus), which control virus replication and induce
anti-viral responses [38,39]. This is consistent with type
I IFN promoting functional activation of DC and cross-
priming of CD8+ T-cells in LCMV-infected mice [40,41].
In contrast to the mouse, the human spleen lacks a mar-
ginal sinus, and MZ surrounds B-cell follicles but not the
PALS (Periarteriolar Lymphatic Sheath or T-cell rich
area). However, the perifollicular zone is an intermediate
area between the MZ and the red pulp (Figure 1). This
zone presents strong similarities to the red pulp because
of terminal sinuses, blood-filled spaces, sheathed capillar-
ies without endothelial lining, and scattered B- and T-
cells. Because terminal vessels directly open into the
perifollicular zone, Ags and leukocytes likely exit the cir-
culation in this structure and traffic either to the MZ or to
the red pulp [42,43]. A meshwork of fibroblast-like cells
expressing Alpha Smooth Muscle actin (ASM) and
MadCAM-1 (Mucosal addressing cell adhesion molecule
1) subdivides the MZ into a large inner and a small outer
compartment, the latter being in close contact with the
perifollicular zone. Along the network of ASM-positive
cells, a small ring of B-cells delimits the T-cell zone from
the red pulp, whereas a ring of T-cells is frequently
present between the inner and outer MZ [44]. The MZM
and MMM subsets that respectively populate the outer
and inner MZ in mice are lacking in humans. However,
human macrophages expressing CD68 (lysosome/macro-
sialin) and CD169 preferentially form sheaths around ca-
pillaries in the perifollicular area, and they can also be
present as scattered cells expressing DC-SIGN [45,46].
Whether these macrophages may replace MZM in trap-
ping pathogens and interacting with MZ B-cells remains
to be established. In humans, CD11c+ CD205+ DCs are
also intertwined with MadCAM1+ cells at the inner
border of the perifollicular zone, whereas BDCA-2+ plas-
macytoid DCs are present in the MZ and T-cell zones
under steady-state conditions [47-50].
Marginal zone B-cells are essential for MZ organisation
and functions
When mature B-cells are gradually depleted experimen-
tally in mice, or when BcR signalling is impaired from
the time of birth, MMM and SIGN-R1+ MZM are ab-
sent from the MZ, leading to the decreased expression
of MadCAM-1 in the marginal sinus and to a lack of re-
sponse to TI Ags [29,35,51]. MadCAM-1 expression,
which is essential for proper trafficking of DC and
macrophages in the MZ during immune responses and
normal marginal sinus organisation, depends on per-
manent interactions between membrane lymphotoxin β
(LTβ) expressed by lymphoid cells and its receptor
expressed by sinus lining endothelial cells [52,53]. While
MZ B-cells can provide LTβ signals that induce
MadCAM-1 expression during adult life, naïve follicular
B-cells and as yet unknown non-lymphoid cells deliver
signals requested during mouse and likely human neo-
natal life [53]. Recent data on subcutaneous infection of
mice by VSV (Vesicular Stomatitis Virus) have demon-
strated that CD169+ macrophages in the subcapsular
sinus of lymph nodes have neuroprotective functions
[54]. Similar to the situation in the spleen MZ, B-cell
derived LTβ renders these CD169+ macrophages capable
of replicating VSV and of producing type I IFN. There-
fore, B-cells exert a critical innate function in antiviral
immunity by maintaining the specific location, pheno-
type and functions of CD169+ macrophages in the
spleen MZ as well as in the subcapsular lymph node
sinus according to the route of virus entry.
In addition to LFA1 and α4β1 (VLA-4, very late anti-
gen-4) integrins [55], S1P1 and S1P, receptors 1 and 3 of
sphingosine-1-phosphate, contribute to the retention of
MZ B-cells in the MZ, whereas follicular B-cells expres-
sing higher levels of CXCR5 freely circulate towards the
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white pulp [56]. Thus, the balance between sphingosine-
1-phosphate and CCL21/CXCL13 plays a determining
role in the integrity of the marginal sinus and the reten-
tion of MZM and MZ B-cells [57-59]. Impaired CCL21
production correlates with a loss of MZM and reduced
pathogen clearance after infection by Leishmania dono-
vani [57,60]. These data clearly demonstrate that the
proper positioning of MZ B-cells is strongly dependent
on the integrity of the sinus-lining cells [52], and that B-
cells are crucial for the development (follicular B-cells)
and maintenance (MZ B-cells) of a functional spleen
MZ or its equivalent in the subcapsular sinus of lymph
nodes.
MZ B-cells: a particular subset of memory B-cells in humans
In mice, orientation towards follicular or MZ B-cell dif-
ferentiation pathways likely depends on the interplay be-
tween BcR and Notch2 signalling. Although absent from
the BM, Delta-like 1, a ligand of Notch2, is expressed by
splenic red pulp venules and possibly by some stromal
cells. No MZ B-cells develop in mice conditionally defi-
cient for Notch2 or Delta-like 1 [61,62]. Follicular B-
PAX5 CD3 ASM DAPI
PAX5 CD3 ASM DAPI
GC
OMZ
T
B
C
TZ
BZ
RP
A B
B-cell ring
Figure 1 Organisation of the follicular and MZ B-cell compartments in the human spleen. (A) Schematic representation of the various T-
and B-cell areas in the human spleen. PALS: periarteriolar lymphatic sheath (T-cell zone). (B) Staining of paraffin-embedded sections of human
spleen with CD20 mAb revealed B-cell follicles (BZ) and a ring of B-cells separating the T-cell zone (TZ) from the red pulp (RP) (original
magnification x10). (C) Sections of human spleen were simultaneously stained with PAX5, CD3 and ASM (alpha smooth muscle actin) mAbs. The
network of fibroblast-like cells stained with the anti-ASM mAb (blue) subdivides the outer (OMZ) from the inner marginal zone around B-cell
follicles (PAX5+, green) and separates the T-cell zone (CD3+, red) from the RP (left panels) (original magnification x10). In the upper left panel, a
germinal centre (GC) is visible within the B-cell follicle. General tissue organisation is shown by DAPI staining of nuclei (right panels).
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cells develop in a Notch-independent, but a BcR- and
BtK-dependent, fashion [63,64]. As shown by Loder
et al., the progression from immature B-cells into ma-
ture B2 B-cells is accompanied by a proliferative burst
and is governed by a BcR-mediated selection process
[65]. According to the “signal-strength” model proposed
by Pillai and co-workers, the strength and duration of
the BcR signal play a determining role in the differenti-
ation of either follicular or MZ B-cells (Figure 2). In-
deed, when self-antigens trigger BcR poorly, the
downstream BtK signalling pathway is insufficient to
prevent transcription of Notch2-related genes. BAFF (B-
cell activating factor of the TNF family) then allows the
survival of these B-cells, which thus differentiate into
MZ B-cells. Conversely, when BcR is strongly triggered
by “high-affinity” self-antigens, B-cells differentiate in a
BtK-dependent manner into follicular B-cells [61,63,66].
Reciprocally, only strong BcR signals leading to potent
Btk activation can counteract the Notch2-induced cleav-
age initiated by Delta-like 1 (Figure 2). Therefore, weak
signals delivered by the BcR appear to be permissive for
MZ B-cell development [61,66].
Mouse and human MZ B-cells can be distinguished from
follicular naïve B-cells as being SIgMhiCD21hiSIgDlo and
CD23-. In humans, MZ B-cells are CD27+ memory B-cells
that express somatically mutated Ig VH genes [67-69]. As
compared with naïve B-cells, blood and spleen MZ B-cells
harbour shorter length VH CDR3 in adults but also in
young infants, indicating that selection can take place in
the absence of antigenic responses [70]. By means of H-
CDR3 spectra typing on B-cell subsets present in CD40-
and AID-deficient infants compared with age-matched
healthy infants, Weller et al. have established that MZ B-
cells mutate their BcR independently of Ag driven immune
responses [69,71,72]. The frequency of VH gene mutation
in blood MZ B-cells reaches adult values by two to four
years of age, and MZ B-cells express a higher clonal diver-
sity than in other memory B-cells in adult individuals
[69,71]. These authors therefore suggested that MZ B-cells
express a “pre-diversified” Ig repertoire specialised in their
response to TI Ags [69,72]. BAFF (produced in the MZ)
has been proposed to be a key contributor to the diversifi-
cation of the MZ B-cell repertoire through Activation
Induced cytidine Deaminase (AID)-dependent mechanisms
[73]. However, only very rare MZ B-cells express AID in
human spleen: this suggests that alternative processes exist
(although they have not yet been identified) [74]. BAFF is a
key survival factor for MZ B-cells that also favours the
Figure 2 Becoming a follicular or a MZ B-cell?. Left panel: Strong signalling through BcR activates Bruton's tyrosine kinase (BTK), which in
turn activates the canonical nuclear factor-kB (NF-kB) signalling pathway and prevents the cleavage of Notch2. BAFF-BAFF-R interactions deliver
survival signals through NF-KB activation. Right panel: Notch2 can interact with its ligand, Delta-Like 1 (DL1), specifically expressed by the
endothelial cells of red pulp venules in mice. This interaction initiates the cleavage of Notch2, which is not inhibited by weak BcR signalling. The
intracellular domain of Notch2 enters into the nucleus where it interacts with Mastermind-like 1 (MAML1) and RBP-J transcription factors. This
transcriptional complex induces the commitment of B-cells towards MZ B-cells. BAFF-BAFF-R interactions deliver survival signals through
canonical NF-KB activation.
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survival of self-reactive B-cells when it is overproduced lo-
cally in response to viral infection or chronic inflammation
[75]. Deregulated BAFF expression is a feature of numer-
ous autoimmune diseases such as rheumatoid arthritis,
lupus erythematosis and Sjögren’s disease, where functional
BAFF would promote the emergence/survival of self-
reactive pathogenic B-cells [75]. In patients with Sjögren’s
disease, where BAFF is locally produced by salivary epithe-
lial cells and infiltrating CD8+ T-cells [76], BAFF levels cor-
relate with autoantibody levels in serum [77]. Mice
transgenic for BAFF can develop Sjögren-like syndromes
characterised by expansion of pathogenic B-cells with an
MZ-like phenotype. Depletion of MZ B-cells totally pre-
vents this syndrome but does not prevent nephritis, which
is also observed in these mice [78]. Consistent with a pos-
sible association between viral infection and Sjögren syn-
drome, Ittah et al. have shown that triggering of TLR3 by
synthetic agonists or dsRNA does induce exaggerated
BAFF production by salivary gland epithelial cells [79].
More recently, these authors have suggested a comprehen-
sive role of viral infection in BAFF production by epithelial
cells and monocytes through Type I IFN-dependent and
independent mechanisms [80]. In macaques experimentally
infected with a pathogenic strain of Simian Immunodefi-
ciency Virus (SIV), we have recently described elevated
plasma levels of BAFF, but not APRIL (A Proliferation-
Inducing Ligand), during the acute phase of infection [81].
The proportions of MZ B-cells strongly decreased in blood,
lymph nodes and spleen because of increased apoptosis
and their differentiation into polyclonal plasma cells
located in the MZ and lymph node sinus, where BAFF
over-expression was concurrently observed [81,82]. There-
fore, cognate interactions with the virus and virus-induced
cytokines likely synergize to promote MZ B-cell differenti-
ation into multi-reactive plasma cells during acute SIV in-
fection. In contrast, the over-expression of BAFF within
GCs would impair the selection process of SIV-specific
plasma cell precursors, contributing to the delayed SIV-
specific antibody detection [81,82]. We are currently
addressing this question in SIV-infected macaques treated
or not with BR3-Fc, a BAFF antagonist currently used for
treating patients with rheumatoid arthritis or lupus
erythematosis.
Marginal zone B-cells: a dual role in T-independent
and T-dependent responses
Interactions of MZ B-cells with pathogens (particularly
bacteria) elicit their rapid activation and secretion of
IgM, which constitutes the first line of defence against
these pathogens. The IgM molecules produced are of
low affinity but exhibit a broad specificity, meaning that
they can bind a variety of Ags with overlapping or close
epitopes, favouring the neutralisation and clearance of a
larger variety of (bacterial and viral) pathogens. In
addition to their role in the innate response, MZ B-cells
are endowed with the ability to import high molecular
weight Ags (>200 kDa) and viral particles into follicles, a
mechanism that can accelerate the adaptive response
against pathogens and widen the repertoire of Ags
present in GC [56]. In most cases, stimulation of these
MZ B-cells occurs independently of the BcR, through
triggering of TLRs or other PRRs. Through their ca-
pacity to shuttle between MZ and B-cell follicles, MZ
B-cells rapidly transport IgM-containing immune com-
plexes delivering pathogen-derived Ags and/or viruses
into B-cell follicles where they can rapidly stimulate the
onset of primary TD responses [56,83]. Under physio-
logical conditions, MZ B-cells re-enter the MZ once
they have delivered Ags to follicular DC within GCs
[56,83]. During chronic infection or inflammation, over-
production of type I IFN plays a major role in the long-
lasting sequestration of B-cells within the follicles by
modifying their responsiveness to S1P [84,85]. This B-
cell sequestration would favour Ag delivery to follicular
DC and interactions between rare T- and B-cells with
identical Ag specificity at the border of follicles [56].
Conversely, long-term exposure to type I IFN might
have immunosuppressive effects on the B-cell response
by interrupting the shuttling of MZ B-cells into the
white pulp. Besides type I IFN, we have shown that
BAFF might prolong the follicular sequestration of MZ
B-cells through its ability to preferentially enhance the
chemotaxis of CD27+ memory B-cells to CXCL13, [86].
This might particularly occur during HIV/SIV infection
[82] or chronic inflammatory diseases where type I IFN
and BAFF are concurrently over-produced (Figure 3).
In summary, MZ B-cells, which primarily mount TI
responses with so-called “natural” IgM Abs of low affin-
ity and large specificity to a variety of pathogens, can
also migrate to follicles where they contribute, via har-
boured IgM/pathogen complexes, to the initiation of
another type of Ab response (that of high affinity/
restricted specificity) requiring cognate interactions
with helper T-cells.
Evidence for a protective role of marginal zone B-cells in
systemic bacterial infection
MZ and microbial responses in infants Consistent
with data in mice showing that the marginal sinus
undergoes organisation during the three first weeks of
life [53], ASM expression in infants is rapidly observed
around B-cell aggregates after birth. This “rudimentary”
MZ organisation attains the adult morphology only after
4 months [87]. Based on the expression of CD21 or
CD1c, conflicting data have been reported regarding the
colonisation of MZ by MZ B-cells before 2 years of age.
Indeed, the group of W. Timens reported that naïve but
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not CD21+CD27+ B-cells were present in the MZ prior
to the age of 2 years, and they additionally showed that
MZ B-cells increased in numbers between the ages of 2
and 5 years, where they reached adult levels [87]. More-
over, even if switched CD27+ memory B-cells can be
generated in vaccinated infants at 4 to 6 months after
birth, they are unable to home into MZ as they do in
adults. Responses to polysaccharides occur concurrently
with the expression of CD21 in the MZ [88]. Therefore,
cellular components other than MZ B-cells are probably
absent or not fully functional before the age of two,
which limits their homing/sequestration in MZ. In con-
trast, Weill et al. observed CD1c expression in the
spleen MZ in 8-month-old infants; they also consistently
detected B-cells with a MZ B-cell phenotype in spleens
of infants below 2 years of age [72]. However CD1c was
previously demonstrated to be expressed by about 50%
of spleen and blood B-cells, and to be consistently
present on mantle zone, likely naïve, B-cells [89]. While
definitive conclusions regarding the kinetics of MZ col-
onisation by MZ B-cells require additional studies, it is
clear that MZ is not fully functional below 2 to 4 years
of age, an observation consistent with high susceptibility
of children less than 2–3 years of age to infections by
encapsulated bacteria and defects in long-lasting protec-
tion towards the polysaccharide pneumococcal vaccine
[90,91]. Bearing in mind the importance of the dialogue
between MZ B-cells and either macrophages or DC sub-
sets in mice, one can speculate that the homing of these
populations within the human MZ plays a similar crucial
role in MZ function. However, little is known about the
kinetics and the precise nature of DC and macrophages
that populate the MZ during the first months of life and
their capacity to express integrins, BAFF/APRIL, and
chemokines known to regulate the homing and survival
of MZ B-cells in situ. Neutrophils may play a previously
underappreciated role as potent producers of BAFF/
APRIL and IL21 in the perifollicular zone of human
spleen that supports Ig class switching, somatic muta-
tion and Ab production by MZ B-cells [92].
Lessons from aging, splenectomy and diseases.
Aging in humans and mice is associated with a decline
in protective immunity and increased susceptibility to
infection by encapsulated bacteria, increased auto-
immune manifestation, and reduced response to
Marginal Zone
S1Phigh, CXCL13low
MGZ B-cells
SP1+, SIP3+
Red Pulp
Blood
T-cell Zone 
Lymph
S1Phigh, CXCL13low
S1Plow
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Immune 
complexes
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Virus,
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Figure 3 MZ B-cells shuttle between the MZ and follicles and transport Ag and pathogens to follicular DC. In steady-state conditions,
strong expression of LFA1 and α4β1 integrins and receptors 1 and 3 of Sphingosine 1-Phosphate (S1P) on MZ B-cells, together with high levels of
S1P in blood, contributes to the retention of MZ B-cells within the MZ. Type I IFN produced in response to blood-borne pathogens inactivates
S1P1 and 3, allowing MZ B-cells to migrate in response to CXCL13, which is highly expressed in follicles. During this relocation, MZ B-cells can
transport immune complexes bound to non-BcR receptors and deliver them to follicular DC (FDC). Once on FDC, these import Ags participate in
the adaptive Ab response [56,83]. Rapid ligand-induced desensitisation of CXCR5 authorizes MZ B-cells to return to the MZ. Overproduction of
BAFF, which preferentially increases the chemotaxis of CD27+ MZ and memory B-cells to CXCL13 might also impair this shuttling and lead to
prolonged sequestration of MZ B-cells within follicles [86]. Such a mechanism would be at work during acute infection by SIV, where it might
favour sequestration of activated B-cells within follicles [82].
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vaccination. Decreased responses to TI antigens in old
mice have been associated with reduced proportions of
MZMs and MZ B-cells, collapse of MZ architecture, and
disturbed MadCAM-1 expression by sinus lining cells
[52]. In humans, invasive pneumococcal disease increases
with age, over 65 in particular [93]. The inefficient Ab re-
sponse in aged individuals is thus assumed to be asso-
ciated with altered functions of the spleen MZ [88,94].
Individuals with splenic dysfunction or having undergone
splenectomy are highly susceptible to infection with
Streptococcus pneumonia, Heamophilus influenza, Neis-
seria meningitis and other encapsulated bacteria, which
correlates with a defect in circulating MZ B-cells and a
lack of Ab response against these pathogens [95]. In
patients with common variable immunodeficiency, those
presenting with recurrent infection of the respiratory tract
and chronic lung disease have an extremely low frequency
of IgM memory B-cells and do not produce anti-
polysaccharide IgM [96,97]. Splenic dysfunction may also
occur in patients with sickle cell anaemia [98], inflamma-
tory bowel disease [99] or celiac disease [100], where both
impaired IgM production by MZ B-cells and reduced
phagocytosis of opsonised particles prevent the clearance
of encapsulated bacteria.
Taken together, these observations indicate that the
spleen exerts a dedicated function that is not completely
substituted by other secondary lymphoid organs. It is
noteworthy, however, that a normal blood MZ B-cell
compartment is present in young children with congeni-
tal asplenia, suggesting that MZ B-cell precursors can
colonize alternative sites for their development [69].
Similarly, cells with the morphology and phenotypes of
MZ B-cells have been observed in the subcapsular sinus
of lymph nodes, under the dome epithelium of Peyer’s
patches in the gut, and in the crypt epithelium of tonsils
[101-104]. Whether these cells have a similar role to
spleen MZ in the defence against encapsulated bacteria
remains to be established. Recent data showing the
unique ability of B-cells to maintain the location and
functions of subcapsular CD169+ macrophages during
innate antiviral immunity strongly support this hypoth-
esis [54].
Human B-cells express Toll-like receptors that define
anatomical and functional subsets
TLRs are commonly divided into two subgroups de-
pending on their cellular localisation and respective
PAMP ligands. The first group is composed of TLR1,
TLR2, TLR4, TLR5, TLR6 and TLRs 10–13, which are
expressed on cell surfaces and recognize mainly micro-
bial surface components. The second group is composed
of TLR3, TLR7, TLR8 and TLR9, which are preferentially
sequestered in the endoplasmic reticulum in resting cells
and rapidly traffic to endolysosomes after stimulation by
microbial nucleic acids [105]. In contrast to mouse B-
cells, human B-cells express neither TLR4 nor CD14,
the two canonical ligands for Gram– bacteria LPS, and
are therefore unresponsive to LPS. In healthy donors,
circulating naïve and memory B-cells express distinct
amounts of TLR1, 2, 6, 7, 9 and 10 and are negative for
TLR 3–5 and 8 [3,10,106]. However, elegant studies by
Cerutti’s group have clearly shown that functional TLR3
is expressed by human tonsillar B-cells, with higher ex-
pression in GCs and sub-epithelial regions, but is absent
from memory B-cells. In the presence of dsRNA, these
mucosal B-cells up-regulate AID expression and initiate
class switch recombination and IgG/IgA production in
the presence of IL-10 and BAFF [107]. Restricted to a
discrete population of CD27– blood B-cells with inter-
mediate levels of CD19, TLR2 is preferentially expressed
by naïve and GC B-cells present in mucosa or exposed
to inflammatory stimuli. MZ B-cells, as well as mucosal
follicular naïve B-cells, strongly express TLR2/TLR1 and
TLR2/TLR6 complexes and thus recognize a panoply of
unrelated molecules, including peptidoglycans, diacy-
lated and triacylated lipopeptides, and porins from a
broad spectrum of microbes [108]. BcR cross-linking
with anti-Ig antibodies or protein A from Staphylococcus
aureus sensitizes B-cells to TLR2-active diacylated and
triacylated lipopeptides, which promote their prolifera-
tion and differentiation into IgM-producing cells
[106,109]. Accordingly, TLR2 ligands are effective adju-
vants in humans and are currently used in the Haemo-
philus influenzae type B vaccine. In vitro, TLR2 ligands
also induce CCR9, CCR10 and J chain expression on
human B-cells and enhance IgA production [23], sug-
gesting that TLR2 activation might favour intestinal
homing. It is not clear yet whether this effect ameliorates
the mucosal response or induces tolerance.
In humans, TLR9 expression is restricted to B-cells
[10], plasmacytoid DCs (pDCs) [7] and platelets [110],
whereas TLR7 is more widely distributed among the
various populations of APCs. TLR7 and TLR9 are con-
sistently present in all B-cell subsets, with the majority
of TLR molecules sequestered in the endoplasmic
reticulum. Activation of TLR9 requires its cleavage by
endolysosomal proteases [111], and TLR9 is detectable
within small intracellular vesicles of primary B-cells
[112]. Memory B-cells contain higher amounts of TLR9
than naïve B-cells [113], and we found that a fraction of
TLR9 molecules can traffic to the plasma membrane
[10]. BcR- and CD40-mediated stimulation transiently
increases TLR9 expression, which enhances responsive-
ness to its agonist, CpG DNA, proliferation, chemokine
production and APC function [7,114]. Besides BcR and
CD40 ligation, Type I IFN produced by pDCs increases
TLR7 and MyD88 expression in naïve peripheral human
B-cells [115], and therefore their responsiveness to TLR7
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agonists. Mouse TLR10 is not functional because of a
retroviral insertion, and TLR11–13 have been lost from
the human genome [105]. While TLR10 expression is
also restricted to B-cells and pDCs, its role in B-cell
physiology remains to be clarified in the absence of rec-
ognition of any specific ligand. Human TLR10 is
strongly related to TLR1 and 6 and associates with
TLR2. While TLR10/TLR2 complexes recruit MyD88
after TLR2 ligand-induced stimulation, they fail to acti-
vate typical TLR-induced signalling, including NF-κB
[105]. However, it seems likely that TLR10 is functional
because TLR10 gene variants have been associated with
susceptibility to asthma [105].
Thus, TLR expression is constitutive in human B-cells,
assigning these cells a functional role in sensing infectious
danger and participating in innate immunity; this function
is well understood in mucosal surfaces but less so in other
compartments. There are indications that B-cells display
various arrays of TLR molecules that seem to characterize
subsets. A question that is beginning to be addressed is
whether TLR binding of pathogen-derived material tethers
pathogen-derived Ags when the BcR is of low affinity
(IgM). This may be the case for MZ B-cells, although this
has not yet been ascertained because of the puzzling obser-
vation that MZ B-cells are CD21hi. The consequences of
dual B-cell stimulation through a PRR (e.g., a TLR) and
BcR deserve further exploration, particularly on Ab
responses initiated by a TI Ag.
Cross-talk between CD1d+ MZ-B-cells and NKT cells
Recent studies have demonstrated that in addition to the
BcR-mediated uptake described for specific lipid Ags
[116,117], B-cells can use an apolipoprotein-mediated
pathway of lipid Ag uptake for presentation to innate-
like NKT cells. Indeed, invariant NKT-cells (iNKT), a
subset of NKT-cells, recognize exogenous and self-lipids
as well as glycolipid Ags (LPS-free) presented by CD1d,
a non-classical class I molecule. Through their charac-
teristically high expression of CD1d, MZ B-cells may es-
tablish cognate interactions with iNKT in the MZ [118]
and elicit a stronger lipid-driven NKT-cell stimulation
than follicular B-cells [119]. The uptake of lipid Ags
requires the expression of the low-density lipoprotein re-
ceptor (LDL-R) by B-cells, a BcR-independent uptake
pathway [120] that probably favours the production of
“polyreactive” (innate), and even self-reactive, Abs.
While the BcR-mediated route facilitates the uptake of
particulate lipid Ags and their transport to CD1d-
containing endocytic vesicles, this pathway likely favours
a more lipid-specific Ab response [118] (Figure 4). Al-
though direct stimulation of TLR2, 7 and 9 by their
ligands elicits IL-6, IL-10 and IFNβ (TLR9 only) produc-
tion by MZ B-cells in mice, it does not result in cognate
interactions with iNKT [121]. These results show that
MZ B-cells may differentially contribute to humoral im-
munity according to their activation route and the na-
ture of the Ag. Moreover, part of the innate Ab response
depends on rapid but transient cognate interactions be-
tween MZ B-cells and NKT-cells. Recent studies have
shown that impaired CD1d recycling in patients with
systemic lupus erythematous, as compared with healthy
individuals, causes defective B-cell mediated iNKT
stimulation. This work highlights the physiological im-
portance of B-cells in lipid presentation to iNKT during
the innate immune response [122].
The case of regulatory B-cells in mice and their potential
equivalents in humans
B-cells are generally considered positive regulators of the
immune response (their major regulator in Ig secretion
function being Ig binding through the FcγRIIb itself ).
However, several regulatory B-cell subsets can negatively
regulate these immune responses [123-125]. A general
feature of these regulatory B-cells is to preferentially
produce IL-10 upon appropriate stimulation [126-128],
Figure 4 MZ B-cells at the crossroad between BcR-dependent
and CD1d-dependent B-cell responses to lipid antigens.
Through the expression of LDL-R, MZ B-cells capture and internalize
aliprotein E (ApoE)-bound lipid Ags. Dendritic cells and
macrophages in tissues secrete ApoE, which is present at low levels
in human serum. ApoE-lipid Ag complexes are directed into the
endosomal-lysosomal pathway and charged onto CD1d molecules.
Exogenous lipids presented by CD1d interact with the invariant TCR
of iNKT. These cognate interactions activate iNKT, which produces
cytokines, and provide “innate help” to MZ B-cells. Because this
internalisation pathway is independent on BcR, it might enhance
humoral responses or induce pathogenic Abs [120]. The LDL-R-
CD1d-dependent pathway for lipid Ag uptake by B-cells
nevertheless provides a mechanism for the adjuvant effects of
αGalCer [116]. Other studies suggest that αGalCer is routed to the
endosomal-lysosomal pathway and charged onto CD1d molecules
after BcR-mediated uptake of protein Ags linked to αGalCer [117],
while BcR-mediated stimulation of human
B-cells rapidly down-modulates CD1d expression [118].
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but this is not a unique feature. In particular, B10, a potent
regulatory B-cell subset within the rare CD1dhiCD5+
B-cell subset of the spleen, has been shown to regulate
acute inflammation and autoimmunity through the pro-
duction of IL-10 [126,127]. Based on the expression of
TIM-1 (T-cell Ig domain and Mucin domain protein 1),
mouse B10 cells can be further distinguished from B-1a
and MZ B-cells [129]. BAFF was recently shown to induce
or expand B10 cells in mice [130].
Data obtained following B-cell depletion by treatment
with Rituximab (a chimeric CD20 mAb), Ofatumumab
or Ocrelizumab (two fully humanised anti-CD20 mAbs)
in patients with autoimmune diseases or having under-
gone BM transplantation strongly support the existence
of regulatory B-cells in humans [131]. However, it is not
clear whether they constitute a distinct lineage or a sub-
set, and have sufficient plasticity to change their effector
functions into regulatory ones. IL-10-producing regula-
tory B-cells have been described in healthy individuals,
as well as in patients with autoimmune disease
[132,133]. In contrast to mice where B10 cells are naïve
B-cells, human IL-10-producing B-cells have been char-
acterised either as memory (CD27+) or immature transi-
tional (CD38hiCD24+) B-cells. Only a population of
human CD19+CD24hiCD38hi B-cells was shown to exert
regulatory functions on CD4+ T-cells [134]. Recent data
from Iwata et al. partially reconcile these data by show-
ing that both human B10 cells and their precursors be-
long to a CD24hiCD27+ B-cell population [133]. Thus,
human B10 cells, similar to MZ B-cells, differ from
mouse B10 cells by expressing a memory phenotype.
The distinct organisation of MZ in mouse and human
probably facilitates different interactions between MZM,
DC and B-cell subsets [135]. In this context, it will be
important to better identify BAFF-producing cells in
human MZ because BAFF is likely involved in the differ-
entiation or survival of human B10. Indeed, treatment of
patients with multiple sclerosis (MS) with Atacicept
(TACI-Ig), an antagonist of BAFF and APRIL, led to an
unexpected increase in inflammatory activity and con-
demned the Atacicept trials in MS [136]. These data
strongly support the notion that human B10 cells are
also dependent on BAFF. While the various human B10
subsets produce IL-10 only after appropriate stimulation,
a distinct population of CD20+CD27+CD43+CD11b+ B1
cells produce it spontaneously [137]. This population
also down regulates the T-cell response. The respective
role of these various IL-10-producing cells deserves to
be extensively examined.
CD21lo/- B-cell populations: from aging to HIV infection
As previously discussed, ageing is accompanied by com-
promised immune responses and an increased propensity
for autoimmunity. Besides reduced numbers of both
hematopoietic stem cells entering into the lymphoid
lineages and of MZ B-cells, accumulation of an exhausted
B-cell population has recently been reported in aged mice
[138]. With no surface CD21, CD23 and CD43, these
CD19hi SIgM+ BAFF-R+ B-cells differ from MZ, B1 and
follicular B-cells. These B-cells further exhibit impaired
functional responses to CD40 and BcR ligands, and to
BAFF, and produce IgM, IL-4 and IL-10 only in response
to TLR9 and TLR7 stimulation. Moreover, these B-cells are
prone to induce IL-17 production by activated T-cells at
the expense of T follicular helper cell generation, thus
thwarting the interactions necessary for affinity maturation
and memory cell formation [139].
In aged female mice and in mice presenting with auto-
immune pathologies, an accumulation of CD21lo/-CD11c+
B-cells has also been described [140]. These CD11c+CD21-
B-cells, which are also CD5+ and CD138+, express high
levels of CD95, CD80 and CD86. Unresponsive to BcR
triggering, these B-cells secrete high levels of anti-
chromatin IgG following TLR7 stimulation. Intact TLR7
signalling is required for the development of this popula-
tion in mice. In humans, this population of CD21- CD11c+
B-cells is CD5hiCD80hiCD86hiCD20hiCD23-, but CD27hi,
and does not express any surface immunoglobulin; it
therefore resembles plasmablast precursors [140]. A high
frequency of circulating CD21lo B-cells is associated with
a propensity to autoimmunity, and the CD21loCD11c+
population is found more frequently in the blood of
elderly female patients with autoimmune disorders than
in healthy age-matched individuals [11,141]. First described
by Ehrhardt et al. as a unique population of memory
B-cells expressing mutated BcR but not CD27, the FcRL4+
(Fc receptor-like protein 4) population normally resides
in epithelial tissue-associated niches [142-145], but is
expanded in the blood of patients with common variable
immunodeficiency [146]. Because FcRL4 disrupts immune
synapse formation and blocks antigen-induced BcR signal-
ling, FcRL4+ B-cells are unresponsive to BcR ligands, but
still responsive to CD40L, TLR9 agonists, IL 2 and IL 10
[147]. In viremic HIV-infected patients and patients
chronically exposed to plasmodium falciparum, this popu-
lation of FcRL4+CD27- memory B-cells was found in the
blood, where it progressively replaces conventional mem-
ory B-cells. In these HIV+ patients, FcRL4+ B-cells showed
reduced proliferation and differentiation into plasma cells
in response to BcR ligands, and also to cytokines and
CD40L [148]. In light of this pathogen-induced loss of
functions, Moir et al. called these cells “exhausted” mem-
ory B-cells. The role of FcRL4 in exhaustion is obvious:
downregulation of FcRL4 expression by RNA interfer-
ence in CD27– memory B-cells in HIV-infected
patients partially restores their capacity to respond to
BcR stimulation and to produce HIV-specific anti-
bodies [149]. At least in HIV-infected patients, these
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Table 1 Summary of main phenotypic and functional characteristics of B-cell subsets
Phenotypic marker Functions and other characteristics References
Marginal Zone B-cells
SIgMhi SIgDloCD27+ CD21hi Mutated BcR in humans on >80% MZ B-cells 67-69,72
CD23- TI-Ab response. Produced Low affinity IgM
CD21 modulates BCR signalling 141
CXCR5+ S1P1hi S1P3hi Preferential sequestration in MZ, shutling into follicles upon stimulation 55, 56, 58, 59
BcR-independent transport of high MW Ags and virus particles into GC 56,83
Present in periphery (blood, Lymph node, spleen) in humans 69
TLR 2> 1, 6; TLR10 Surface TLRs associated into functional TLR2/1 or TLR2/6 complexes 108, 109
TLR9>7 Endosomal TLR detecting unmethylated CpG DNA and ssRNA
CD1chi Expression ↘ upon CD40L stimulation but ↗ after BcR triggering 115
LDL-R+ Binds and internalizes lipid Ags associated with Apo-E 117
CD1dhi Presents lipid Ags to iNKT 116, 119-122
CD1d expression decreases rapidly after BCR or CD40 activation 118
Cognate interactions with iNKT, which in turn produce IL17 and IL22 119-122
BAFF-R++, TACI+ Strong expression of their ligand, BAFF, in MZ. Survival of MZ B-cells. 75
Role of BAFF in the transient relocalisation of MZ B-cells into follicles
Follicular Naive B-cells
SIgM+ SIgDhiCD27- CD21+CD23hi Unmutated BcR.
CXCR5++ S1P1+ S1P3- Preferential homing to follicles 56
TLR 2> 1, 6, TLR10 Surface TLRs associated into functional TLR2/1 or TLR2/6 complexes 108,109
TLR9>7 Endosomal TLR detecting unmethylated CpG DNA and ssRNA,
CD1c+, CD1dhi Functional role? 118
BAFF-R++, TACI+ Naive B-cell survival
Conventional Memory B-cells
SIgD-, SIgG/A>SIgM, CD27+ High affinity hypermutated BcR
CD21hiCD23- Role of CD21 in memory B-cell survival 141
TLR9++, TLR7+ ↗ expression of TLR 7, 9 in memory B-cells compared to naive B-cells 7,113
BAFF-R+TACI+ BAFF preferentially enhances memory B-cell chemotaxis to CXCL13 86
Regulatory B-cells
CD1dhi CD5+ TIM-1+ B10:IL10-producing B-cells in mice. Located in/near MZ 123,124
Expanded by BAFF in mice 130
CD27+ IL10-producing memory B-cells in humans 127, 132-134
CD19+CD24hi CD38hi IL10-producing transitional B-cells in humans. Regulatory functions on CD4+ T-cells 134
CD21 lo/- B-cells
CD19+ SIgM+ BAFF-R+ CD21- No response to BcR, CD40 or BAFF-R stimulation 134
CD23-CD43- Production of IgM, IL10 and IL4 in response to TLR9, 7 stimulation
Induce IL17 production by activated T-cells 115
CD21lo CD11c+ CD5+ CD138+ Present in aged and autoimmune mice. Pre-plasmablasts? 157
CD95hi CD80hi CD86hi No response to BcR stimulation but produced IgG after TLR7 triggering
CD20hi CD21lo CD11c+ CD5hiCD27hi Present in blood of elderly female autoimmune patients 132,133
CD23-SIg-CD80hiCD86hi Pre-plasmablasts?
CD21loCD27+ Activated B-cells or pre-plasmablasts present in HIV-infected patients 148-150
CD21loCD27-PD1+ FcRL4+ Exhausted tissue-like memory B-cells present in HIV-infected patients 148-150
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exhausted memory B-cells express high levels of PD-1
(Programmed Death 1) [148]. During pathogenic SIV
infection in macaques, PD-1 drives the rapid and sus-
tained loss of activated memory B-cells (CD21loCD27+)
in the so-called “rapid progressors”. This depletion,
which constitutes an early predictor of disease progres-
sion, can be reversed by blockade of PD-1. In vivo
blockade of PD1 in SIV-infected macaques have
enhanced polyclonal and virus-specific Ab responses
[150]. Whether similar mechanisms/pathways are re-
sponsible for CD21 downregulation in HIV-infected
patients, patients with autoimmune diseases and aged
individuals remains to be firmly established.
Concluding remarks
In conclusion, B lymphocytes display hallmarks of three
distinct functional categories of immune cells (Table 1):
i) they bear a unique B-cell receptor for antigen on their
membranes, which characterizes conventional B-cells
and adaptive immunity; ii) they express CD40 on their
surfaces, a property which is shared by most APC
(though this is not a unique feature); iii) they express
PAMP-ligands i.e. PRRs, which is considered a landmark
of innate immune cells. Indeed, human B-cell subsets
express distinct PRRs, including FcRs, complement
receptors and TLRs. B-cells, despite being from a unique
origin, have diversified into distinct subsets, the survival
and functions of which are associated with their microa-
natomical locations. Accordingly, one can distinguish
four main orientations. The first orientation comprises
conventional, or follicular, B-cells that populate B-cell
follicles in secondary lymphoid organs and mucosa, and
correspond to the B2 lymphocytes in the mouse system.
They principally use their capacity to bind amino acid-
based Ags (although independent of APC and HLA in
the conformational presentation) through the BcR and
are specialised in the response to TD Ag. Qualified as
naïve follicular B-cells before they encounter Ag, they
evolve into activated B-cells that populate GCs and into
memory or long-lived plasma cells that colonize specific
areas around follicles and bone marrow, respectively.
The second orientation concerns MZ non-conventional
B-cells and B1-like B-cells, that can bind either peptide
Ags through their BcR and/or non-peptide Ags such as
lipids and polyosides or nucleic acids via a plethora of
surface receptors. This subset is specialised for TI-Ab
responses and preferentially home in spleen MZ. In con-
trast to follicular B-cells, which are highly recirculating
cells, MZ B-cells have a restricted trafficking pattern.
The third orientation is forwards regulatory B-cells
(Breg), most of which produce high amounts of IL-10
upon appropriate stimulation. They have been identified
both in mouse and humans, and parallel regulatory T-
cells. Like MZ B-cells, Breg mainly locate in the spleen
MZ where their survival and expansion are dependent
on BAFF; In the fourth orientation, there is a novel
complex of CD21lo B-cell subsets that include at least
three different populations: activated memory B-cells
(CD21loCD27+), plasmablast precursors (CD21loCD27-
hiCD11c+CD138+) and “exhausted” memory B-cells
(CD21loCD27loPD1+FcRL4+). Increased numbers of
these B-cell subsets in blood have been preferentially
reported in aged mice and humans, and in patients with
autoimmune diseases or during chronic viral infection.
B-cells belonging to these subsets harbour a non-
functional BcR, and are frequently unresponsive to
CD40L but strongly sensitive to TLR7 or TLR9 agonists.
In healthy individuals, the latter CD21lo population
would preferentially reside in mucosa-associated tissues,
immediately beneath the epithelium, likely sampling in-
vasive pathogens. The identification of these new B-cell
subsets, whose functions and survival are highly
dependent on signals outside of those targeted at BcR,
particularly homing, highlights the previously unex-
pected complexity of the B-cell compartment. It is thus
a novel challenge in immunology to decipher the re-
spective influence of innate and adaptive signals on the
outcome of the B-cell responses in healthy individuals,
and also during aging, autoimmune diseases, and
chronic viral infection. The increasingly complex roles
of B-cells are not yet fully characterised, nor are the dif-
ferences between murine models and the human system
fully determined. Further characterisation of the
remaining mysteries of B-cell compartmentalisation is of
key importance to human pathology, both in the fields
of autoimmune disorders and onco-haematology.
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